Document:

Termination Agreement  - PowderMed, Ltd.

 Exhibit 10.74 
 TERMINATION AGREEMENT 
 This agreement
for the termination of the “Supply Agreement” between Anesiva, Inc and PowderMed, Ltd (the “Parties”) (originally the Supply Agreement between AlgoRx Pharmaceuticals, Inc. and PowderJect Technologies Ltd.) dated
March 22nd, 2002 (as amended) is made and entered into as of the 18th day of December, 2008 (the “Effective Date”). 
 WHEREAS, Anesiva and PowderMed are parties to a
Supply Agreement (originally the Supply Agreement between AlgoRx Pharmaceuticals, Inc and PowderJect Technologies Ltd.) dated March 22, 2002 (as amended) (“the Agreement”); 
 WHEREAS, PowderMed and BOC are parties to a Services, Manufacture and Supply Agreement dated February 21, 2003 (the “SMSA”); 

WHEREAS, PowderMed currently supplies certain gas microcylinders to Anesiva for the manufacture of certain of Anesiva’s products, in particular
the product known as ZingoTM; 
 WHEREAS, Anesiva has informed PowderMed that it will no longer produce and commercialize the product
ZingoTM and has asked PowderMed to immediately cease the supply of gas microcylinders as provided under the terms of the Agreement; 
 WHEREAS, PowderMed and Anesiva desire to effect the termination of the Agreement and the SMSA under certain conditions mutually agreed upon and detailed herein. 
 NOW, THEREFORE, the Parties hereto agree as follows: 
  

	 	1.	The Agreement is hereby terminated as of the Effective Date. 

  

	 	2.	Upon termination of the Agreement, POWDERMED will forego its ongoing right to the 5% royalty payment under section 3.1 of the License Agreement dated March 22, 2002 (as
amended) between the Parties. 

  

	 	3.	POWDERMED will cause the SMSA to be terminated, and upon termination of the SMSA, POWDERMED will grant ANESIVA a non-exclusive, worldwide, royalty-free sublicense (with rights to
further sublicenses upon POWDERMED’s prior consent) under Intellectual Property Rights in the Gas Supply System, that becomes licensed to POWDERMED by BOC or its Affiliates pursuant to the SMSA at any time prior to or after the effective date
of termination of the BOC SMSA, to the extent necessary to manufacture and/or have manufactured gas microcylinders and/or devices containing gas microcylinders. 

	 	 4.
	 Upon termination of the Agreement, POWDERMED will forego the existing financial commitment of ANESIVA for the
2nd, 3rd and 4th quarters of 2008 purchase orders which were already invoiced or currently in the process of being invoiced to ANESIVA (invoice 1000003524 for the amount of
$446,515.20 to cover order 6891 and invoice 1000003541 for the amount of $852,028.80 to cover orders 7445, 7954, together with the royalty payment agreed for the amount of $6,000). 

  

	 	5.	ANESIVA will provide POWDERMED, within 30 days of the Effective date, a notification indicating whether or not ANESIVA would like to have the equipment used in the manufacturing of
gas microcylinders transferred to ANESIVA under the conditions set forth in section 6. If ANESIVA chooses not to want the equipment, POWDERMED will have the right to dispose of the equipment as it sees fit and at its sole discretion.

  

	 	6.	Upon termination of the SMSA and if requested by ANESIVA pursuant to Section 5, POWDERMED will provide ANESIVA, to the extent POWDERMED is able, access to the equipment (pilot
and commercial lines). ANESIVA expressly acknowledges and agrees that the equipment is available on an “as is” basis and that no representations, warranties or any other undertakings of whatever nature (whether express or implied) are
being made by POWDERMED with respect to the equipment and accordingly POWDERMED will not be held liable whatsoever with respect to such equipment. All ongoing costs relating to the maintenance, storage or use of the equipment shall henceforth be
borne by ANESIVA. 

  

	 	7.	Upon termination of the SMSA, POWDERMED will provide reasonable assistance and technical support for the transfer of manufacturing know-how of gas microcylinders to ANESIVA which
must occur at a time not later than March 31, 2009. 

  

	 	8.	Upon termination of the SMSA, POWDERMED will provide ANESIVA with the records and samples that relate to gas microcylinders already manufactured and delivered to ANESIVA.

  

	 	9.	Upon termination of the Agreement, ANESIVA will immediately release and discharge POWDERMED and all of its Affiliates of all obligations under the Agreement including but not
limited to accrued rights and/or surviving obligations under Section 9.5 of the Agreement. 

  

	 	10.	Upon termination of the Agreement, POWDERMED will indemnify and shall keep indemnified ANESIVA against any and all liability, costs, damages and claims made against ANESIVA
resulting from or arising out of the negligence or willful misconduct of POWDERMED or its officers, directors, employees, or agents that occurred during the term of the Agreement. 

	 	11.	Upon termination of the Agreement, ANESIVA will indemnify and shall keep indemnified POWDERMED against any and all liability, costs, damages and claims made against POWDERMED in
connection with any act or omission by ANESIVA occurring after termination of the Agreement and against any and all claims resulting from and arising out of the use of the gas micro-cylinders supplied to ANESIVA (except to the extent that the harm
was caused by a gas microcylinder that was defective upon delivery or that did not conform to the specifications) and/or resulting from or arising out of the negligence or willful misconduct of ANESIVA or its officers, directors, employees, or
agents before termination of the Agreement. 

  

	 	12.	The Parties agree that this “Termination Agreement” shall be governed by and construed in accordance with the laws of the United Kingdom without reference to its choice of
law principles. 

 IN WITNESS WHEREOF, the Parties have executed this Agreement the date and year first above written.

  

					
	Executed by	 		 	Executed by
	POWDERMED, LTD.	 		 	ANESIVA, INC.
	Ramsgate Road, Sandwich,	 		 	650 Gateway Boulevard
	Kent CT13 9NJ	 		 	So. San Francisco, CA 94080
			
	/s/ Annette Doherty	 		 	/s/ Jean Viret
	Name of authorized officer	 		 	Name of authorized officer
	Sandwich Site Leader	 		 	Jean Viret
	22/12/08	 		 	Vice President and Chief
		 		 	Financial OfficerAmendment to Offer Letter - Michael L. Kranda

 Exhibit 10.76 
 March 24, 2009 
 Michael Kranda 
 Dear Michael,

 Anesiva, Inc. (We or the “Company”) is pleased to offer you an amendment to your employment terms, as set forth in the Offer
Letter between you and the Company, dated June 16, 2008 (the “Offer Letter” attached hereto as Exhibit A). The employment terms set forth in this Amendment are effective as of January 1, 2009 (the “Amendment
Date”) unless stated otherwise. Unless this Amendment specifically states that it supersedes an employment term in the Offer Letter, the employment terms of the Offer Letter shall remain binding and in full force and effect. 
 1. Commuting Allowance. In order to assist you in your commuting expenses, we will reimburse you or pay on your behalf up to $70,000
per year for reasonable hotel, airfare, and rental car expenses to commute between Seattle, Washington and the San Francisco Bay Area each year (“Commuting Allowance”). Upon a Change of Control, as defined in the Company’s Amended and
Restated Executive Change in Control and Severance Benefit Plan, or involuntary termination, the payments for the remaining months of the then current year term and all prospective periods will be waived. The Commuting Allowance payments will be
paid in accordance with the Company’s standard travel and reimbursement policy. In addition, we will pay for the reimbursement of commuting expenses incurred in fiscal 2008 of approximately $60,000. 
 2. Outside Activities. While you render services to the Company, you agree that you will not engage in any other employment,
consulting or other business activity without the prior written consent of the Company and you will not serve on more than one for profit entity board of directors without the written consent of the Anesiva Board. Consent of the Company is granted
for your participation in the outside activities described on the attached Exhibit A, to the extent of and for the periods of time described therein. While you render services to the Company you also will not assist any person or entity in competing
with the Company or in preparing to compete with the Company. In addition, while you render services to the Company and for one (1) year thereafter, you will not engage in, and will not assist any person or entity in, soliciting, recruiting, or
hiring away from the Company any active employees or consultants of the Company, unless approved by the Anesiva Board. 
 3.
Employment Relationship. Your employment with the Company is and continues to be “at will,” as described in paragraph 11 of the Offer Letter 
 4. Supersedes. This Amendment supersedes and replaces any prior agreements, representations or understandings, whether written, oral or implied, between you and the Company regarding the employment terms
described in this Amendment, provided that unless specifically superseded, the employment terms of the Offer Letter remain in full force and effect. 
  

			
	Very truly yours,
	
	ANESIVA, INC.
		
	By:	 	/s/ John Tran
		 	John Tran
		 	VP, Finance & Chief Accounting Officer

 I have read, and accept and agree to, this letter agreement: 
  

	
	/s/ Michael Kranda
	Signature of Michael L. Kranda

 Dated: 03/24/2009 
 cc: Compensation Committee 

 Kranda 
 Page 2

  

 Exhibit A 
 Independent Consulting Agreement (“Vulcan Agreement”) with Vulcan Capital: The Vulcan agreement describes the terms upon which Michael Kranda serves as Vulcan’s designee on the boards of specific
portfolio companies. Designated companies are; PTC Therapeutics and BiPar. The Vulcan agreement may be terminated by either party subject to 14 day notice, agreement expires on June 30, 2010 and is expected to be renewed reflecting the
following agreement with Anesiva. 
 PTC: It is understood that Mr. Kranda will continue to serve on the PTC board, either continuing as Vulcan’s
representative under the above mentioned contract or as an independent director subject to the terms and discretion of the PTC Board. 
 BiPar: It is
understood that Mr. Kranda will continue to serve on the BiPar board, either continuing as Vulcan’s representative under the above mentioned contract or as an independent director subject to the terms and discretion of the BiPar Board.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00156-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00156-of-00352.parquet"}]]